Drugs / TBA-7371
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04176250 | Jan 2020 → Oct 2022 | pulmonary tuberculosis | Gates Medical Research Institute | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03199339 Comparator | Aug 2017 → Jul 2018 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBA-7371 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04176250 ↗ |
| Known as | AZ-7371 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3109802 ↗ |
| Modality | Small molecule | — CHEMBL3109802 ↗ |
| Route | Oral | “orally giving 200mg of TBA-7371” NCT03199339 ↗ |